Barclays Maintains Overweight on AnaptysBio, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 77.7%

Neg 0% Neu 0% Pos 77.7%

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $63 to $75.